Hi WAG. I agree the shortened P3 is certainly a incentive to think about going it alone but it also means that for the next year we are solely focussed on Trofinetide P3 for Retts. A partnership deal would open up many more channels and alllow for further development and testing of 2591 which is exciting. Better path forward for the company and shareholders IMO.
NEU Price at posting:
$3.30 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)